Chemotherapy plus therapeutic plasmapheresis with 4% human albumin solution in multiple myeloma patients with acute kidney injury: a prospective, open-label, proof-of-concept study

References

• Padmanabhan A, Connelly-Smith L, Aqui N, et al. Guidelines on the use of therapeutic apheresis in clinical practice – evidence-based approach from the Writing Committee of the American Society for Apheresis: the eighth special issue. J Clin Apher. 2019;34(3):1–13. doi: 10.1002/jca.21705.
   Web of Science ®Google Scholar
• Lameire N, Vanholder R, Van Biesen W, et al. Acute kidney injury in critically ill cancer patients: an update. Crit Care. 2016;20(1):209. doi: 10.1186/s13054-016-1382-6.
   PubMedGoogle Scholar
• Premuzic V, Batinic J, Roncevic P, et al. Role of plasmapheresis in the management of acute kidney injury in patients with multiple myeloma: should we abandon it? Ther Apher Dial. 2018;22(1):79–86. doi: 10.1111/1744-9987.12606.
   PubMed Web of Science ®Google Scholar
• Manook M, Flores WJ, Schmitz R, et al. Measuring the impact of targeting FcRn-mediated IgG recycling on donor-specific alloantibodies in a sensitized NHP model. Front Immunol. 2021;12:660900. doi: 10.3389/fimmu.2021.660900.
   PubMed Web of Science ®Google Scholar
• Díaz F, Cores C, Atenas O, et al. Rationale of therapeutic plasma exchange as rescue immunomodulatory treatment for MIS-C with multiorgan failure. Pediatr Infect Dis J. 2021;40(7):e259–e262. doi: 10.1097/INF.0000000000003169.
   PubMed Web of Science ®Google Scholar
• Diorio C, Henrickson SE, Vella LA, et al. Multisystem inflammatory syndrome in children and COVID-19 are distinct presentations of SARS-CoV-2. J Clin Invest. 2020;130(11):5967–5975. doi: 10.1172/JCI140970.
   PubMed Web of Science ®Google Scholar
• Carter MJ, Fish M, Jennings A, et al. Peripheral immunophenotypes in children with multisystem inflammatory syndrome associated with SARS-CoV-2 infection. Nat Med. 2020;26(11):1701–1707. doi: 10.1038/s41591-020-1054-6.
   PubMed Web of Science ®Google Scholar
• Diorio C, McNerney KO, Lambert M, et al. Evidence of thrombotic microangiopathy in children with SARS-CoV-2 across the spectrum of clinical presentations. Blood Adv. 2020;4(23):6051–6063. doi: 10.1182/bloodadvances.2020003471.
   PubMed Web of Science ®Google Scholar
• Sethi J, Ramachandran R, Malhotra P, et al. Plasma exchange in the management of new onset multiple myeloma with cast nephropathy treated with bortezomib based chemotherapy. Nephrology. 2017;22(12):1035–1036. doi: 10.1111/nep.12979.
   PubMed Web of Science ®Google Scholar
• Leung N, Gertz MA, Zeldenrust SR, et al. Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains. Kidney Int. 2008;73(11):1282–1288. doi: 10.1038/ki.2008.108.
   PubMed Web of Science ®Google Scholar
• El-Achkar TM, Sharfuddin AA, Dominguez J. Approach to acute renal failure with multiple myeloma: role of plasmapheresis. Ther Apher Dial. 2005;9(5):417–422. doi: 10.1111/j.1744-9987.2005.00322.x.
   PubMed Web of Science ®Google Scholar
• Stanworth SJ, New HV, Apelseth TO, et al. Effects of the COVID-19 pandemic on supply and use of blood for transfusion. Lancet Haematol. 2020;7(10):e756–e764. doi: 10.1016/S2352-3026(20)30186-1.
   PubMed Web of Science ®Google Scholar
• Alcorn K, Ramsey G, Souers R, et al. Appropriateness of plasma transfusion: a College of American pathologists Q-Probes study of guidelines, waste, and serious adverse events. Arch Pathol Lab Med. 2017;141(3):396–401. doi: 10.5858/ARPA.2016-0047-CP.
   PubMed Web of Science ®Google Scholar
• McCullagh J, Cardigan R, Brunskill SJ, et al. Assessing the risks of haemolysis as an adverse reaction following the transfusion of ABO incompatible plasma-containing components – a scoping review. Blood Rev. 2022;56:100989. doi: 10.1016/j.blre.2022.100989.
   PubMed Web of Science ®Google Scholar
• Rumman A, Candia R, Sam JJ, et al. Public versus private drug insurance and outcomes of patients requiring biologic therapies for inflammatory bowel disease. Can J Gastroenterol Hepatol. 2017;2017:7365937. doi: 10.1155/2017/7365937.
   PubMed Web of Science ®Google Scholar
• Covington ML, Voma C, Stowell SR. Shortage of plasma-derived products: a looming crisis? Blood. 2022;139(21):3222–3225. doi: 10.1182/blood.2021015370.
   PubMed Web of Science ®Google Scholar
• Bai Z, Chen Y, Dong L. Experience of therapeutic plasma exchange in rheumatic diseases: albumin may be a suitable substitute for plasma. Arch Rheumatol. 2021;36(3):398–408. doi: 10.46497/ArchRheumatol.2021.8447.
   PubMed Web of Science ®Google Scholar
• Yu X, Gan L, Wang Z, et al. Chemotherapy with or without plasmapheresis in acute renal failure due to multiple myeloma: a meta-analysis. Int J Clin Pharmacol Ther. 2015;53(5):391–397. doi: 10.5414/CP202245.
   PubMed Web of Science ®Google Scholar
• Hasan MN, Capuk O, Patel SM, et al. The role of metabolic plasticity of tumor-associated macrophages in shaping the tumor microenvironment immunity. Cancers. 2022;14(14):3331. doi: 10.3390/cancers14143331.
   PubMed Web of Science ®Google Scholar
• Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract. 2012;120(4):c179–c184. doi: 10.1159/000339789.
   PubMedGoogle Scholar
• Joshua DE, Bryant C, Dix C, et al. Biology and therapy of multiple myeloma. Med J Aust. 2019;210(8):375–380. doi: 10.5694/mja2.50129.
   PubMed Web of Science ®Google Scholar
• Ludwig H, Adam Z, Hajek R, et al. Light chain-induced acute renal failure can be reversed by bortezomib–doxorubicin–dexamethasone in multiple myeloma: results of a phase II study. J Clin Oncol. 2010;28(30):4635–4641. doi: 10.1200/JCO.2010.28.1238.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Merlini G, Bridoux F, et al. Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group. Lancet Oncol. 2023;24(7):e293–e311. doi: 10.1016/S1470-2045(23)00223-1.
   PubMed Web of Science ®Google Scholar
• Ahmed S, Kaplan A. Therapeutic plasma exchange using membrane plasma separation. Clin J Am Soc Nephrol. 2020;15(9):1364–1370. doi: 10.2215/CJN.12501019.
   PubMed Web of Science ®Google Scholar
• Wald R, Kirkham B, daCosta BR, et al. Fluid balance and renal replacement therapy initiation strategy: a secondary analysis of the STARRT-AKI trial. Crit Care. 2022;26(1):360. doi: 10.1186/s13054-022-04229-0.
   PubMed Web of Science ®Google Scholar
• Inkinen N, Pettilä V, Valkonen M, et al. Non-interventional follow-up versus fluid bolus in RESPONSE to oliguria in hemodynamically stable critically ill patients: a randomized controlled pilot trial. Crit Care. 2022;26(1):401. doi: 10.1186/s13054-022-04283-8.
   PubMed Web of Science ®Google Scholar
• Little RJA, Rubin DB. Statistical analysis with missing data. 3rd ed. Hoboken (NJ): Wiley; 2020. xii, 449 pp.
   Google Scholar
• D’Agostino M, Cairns DA, Lahuerta JJ, et al. Second revision of the International Staging System (R2-ISS) for overall survival in multiple myeloma: a European Myeloma Network (EMN) report within the HARMONY project. J Clin Oncol. 2022;40(29):3406–3418. doi: 10.1200/JCO.21.02614.
   PubMed Web of Science ®Google Scholar
• Greipp PR, San Miguel J, Durie BGM, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23(15):3412–3420. doi: 10.1200/JCO.2005.04.242.
   PubMed Web of Science ®Google Scholar
• Canaud B, Stephens MP, Nikam M, et al. Multitargeted interventions to reduce dialysis-induced systemic stress. Clin Kidney J. 2021;14(Suppl. 4):i72–i84. doi: 10.1093/ckj/sfab192.
   PubMedGoogle Scholar
• Hryciw N, Joannidis M, Hiremath S, et al. Intravenous albumin for mitigating hypotension and augmenting ultrafiltration during kidney replacement therapy. Clin J Am Soc Nephrol. 2021;16(5):820–828. doi: 10.2215/CJN.09670620.
   PubMed Web of Science ®Google Scholar
• Guzmán-Calderón E, Diaz-Arocutipa C, Monge E. Lactate Ringer’s versus normal saline in the management of acute pancreatitis: a systematic review and meta-analysis of randomized controlled trials. Dig Dis Sci. 2021;67(8):4131–4139. doi: 10.1007/s10620-021-07269-8.
   PubMed Web of Science ®Google Scholar
• Ichai C, Orban JC, Fontaine E. Sodium lactate for fluid resuscitation: the preferred solution for the coming decades? Crit Care. 2014;18(4):163. doi: 10.1186/cc13973.
   PubMed Web of Science ®Google Scholar
• Singh S, Kerndt CC, Davis D. Ringer’s lactate. Treasure Island (FL): StatPearls; 2022.
   Google Scholar
• Rodan AR. Potassium: friend or foe? Pediatr Nephrol. 2017;32(7):1109–1121. doi: 10.1007/s00467-016-3411-8.
   PubMed Web of Science ®Google Scholar
• Fermand J-P, Bridoux F, Dispenzieri A, et al. Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications. Blood. 2018;132(14):1478–1485. doi: 10.1182/blood-2018-04-839480.
   PubMed Web of Science ®Google Scholar
• Bridoux F, Leung N, Belmouaz M, et al. Management of acute kidney injury in symptomatic multiple myeloma. Kidney Int. 2021;99(3):570–580. doi: 10.1016/j.kint.2020.11.010.
   PubMed Web of Science ®Google Scholar
• Liu S, Shang J, Lin Y, et al. Analysis of the clinical effects and outcome of patients with double-hit high-risk multiple myeloma. Zhonghua Zhong Liu Za Zhi. 2021;43(11):1209–1214. doi: 10.3760/cma.j.cn112152-20200109-00016.
   PubMedGoogle Scholar
• Li Q, Hu C-D, Zhang C-C, et al. Predictive value of newly diagnosed IgG level in patients with IgG-type multiple myeloma after initial treatment. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2021;29(6):1825–1830. doi: 10.19746/j.cnki.issn.1009-2137.2021.06.023.
   PubMedGoogle Scholar
• Burnette BL, Leung N, Rajkumar SV. Renal improvement in myeloma with bortezomib plus plasma exchange. N Engl J Med. 2011;364(24):2365–2366. doi: 10.1056/NEJMc1101834.
   PubMed Web of Science ®Google Scholar
• Costa LJ, Abbas J, Ortiz-Cruz KL, et al. Outcomes of patients with multiple myeloma and renal impairment treated with bortezomib, cyclophosphamide, and dexamethasone without plasma exchange. Eur J Haematol. 2012;89(5):432–434. PMID: 22971164. doi: 10.1111/ejh.12008.
   PubMed Web of Science ®Google Scholar
• Johnson WJ, Kyle RA, Pineda AA, et al. Treatment of renal failure associated with multiple myeloma. Plasmapheresis, hemodialysis, and chemotherapy. Arch Intern Med. 1990;150(4):863–869. doi: 10.1001/archinte.1990.00390160111022.
   PubMedGoogle Scholar
• Kalpakci Y, Hacibekiroglu T, Darcin T, et al. Efficacy and safety of plasmapheresis in symptomatic hyperviscosity and cast nephropathy: a multicenter experience in Turkey. Transfus Apher Sci. 2021;60(5):103244. doi: 10.1016/j.transci.2021.103244.
   PubMed Web of Science ®Google Scholar
• Chen F, Leng Y, Ni J, et al. Symptom clusters and quality of life in ambulatory patients with multiple myeloma. Support Care Cancer. 2022;30(6):4961–4970. doi: 10.1007/s00520-022-06896-9.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Jacobus SJ, Cohen AD, et al. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 2020;21(10):1317–1330. doi: 10.1016/S1470-2045(20)30452-6.
   PubMed Web of Science ®Google Scholar
• Gertz MA. Immunoglobulin light chain amyloidosis: 2022 update on diagnosis, prognosis, and treatment. Am J Hematol. 2022;97(6):818–829. doi: 10.1002/ajh.26569.
   PubMed Web of Science ®Google Scholar
• Sethi S, Rajkumar SV, D’Agati VD. The complexity and heterogeneity of monoclonal immunoglobulin-associated renal diseases. J Am Soc Nephrol. 2018;29(7):1810–1823. doi: 10.1681/ASN.2017121319.
   PubMed Web of Science ®Google Scholar
• Sobue Y, Takemura G, Kawamura S, et al. Coexistence of amyloidosis and light chain deposition disease in the heart. Cardiovasc Pathol. 2021;51:107315. doi: 10.1016/j.carpath.2020.107315.
   PubMed Web of Science ®Google Scholar
• Mercado JJ, Markert JM, Meador W, et al. Primary CNS nonamyloidogenic light chain deposition disease: case report and brief review. Int J Surg Pathol. 2017;25(8):755–760. doi: 10.1177/1066896917717338.
   PubMed Web of Science ®Google Scholar
• Dhakal B, Miller S, Rein L, et al. Trends in the use of therapeutic plasma exchange in multiple myeloma. J Clin Apher. 2020;35(4):307–315. doi: 10.1002/jca.21798.
   PubMed Web of Science ®Google Scholar
• Fabbrini P, Finkel K, Gallieni M, et al. Light chains removal by extracorporeal techniques in acute kidney injury due to multiple myeloma: a position statement of the Onconephrology Work Group of the Italian Society of Nephrology. J Nephrol. 2016;29(6):735–746. doi: 10.1007/s40620-016-0347-9.
   PubMed Web of Science ®Google Scholar
• Zucchelli P, Pasquali S, Cagnoli L, et al. Controlled plasma exchange trial in acute renal failure due to multiple myeloma. Kidney Int. 1988;33(6):1175–1180. doi: 10.1038/ki.1988.127.
   PubMed Web of Science ®Google Scholar
• Clark WF, Stewart AK, Rock GA, et al. Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial. Ann Intern Med. 2005;143(11):777–784. doi: 10.7326/0003-4819-143-11-200512060-00005.
   PubMed Web of Science ®Google Scholar
• Wiedermann CJ, Wiedermann W, Joannidis M. Correction to: hypoalbuminemia and acute kidney injury: a meta-analysis of observational clinical studies. Intensive Care Med. 2021;47(2):262. doi: 10.1007/s00134-020-06268-z.
   PubMed Web of Science ®Google Scholar
• Mokrzycki MH, Kaplan AA. Therapeutic plasma exchange: complications and management. Am J Kidney Dis. 1994;23(6):817–827. doi: 10.1016/s0272-6386(12)80135-1.
   PubMed Web of Science ®Google Scholar